Publication:
Shattering the castle walls: Anti-stromal therapy for pancreatic cancer

dc.contributor.buuauthorKanat, Özkan
dc.contributor.buuauthorErtaş, Hülya
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentOnkoloji Ana Bilim Dalı
dc.contributor.scopusid55881548500
dc.contributor.scopusid57195326915
dc.date.accessioned2022-12-23T08:34:26Z
dc.date.available2022-12-23T08:34:26Z
dc.date.issued2018-08-15
dc.description.abstractDespite the availability of potent chemotherapy regimens, such as 5-fluorouracil, folinic acid, irinotecan, and oxaliplatin (FOLFIRINOX) and nab-paclitaxel plus gemcitabine, treatment outcomes in metastatic pancreatic cancer (PC) remain unsatisfactory. The presence of an abundant fibrous stroma in PC is considered a crucial factor for its unfavorable condition. Apparently, stroma acts as a physical barrier to restrict intratumoral cytotoxic drug penetration and creates a hypoxic environment that reduces the efficacy of radiotherapy. In addition, stroma plays a vital supportive role in the development and progression of PC, which has prompted researchers to assess the potential benefits of agents targeting several cellular (e.g., stellate cells) and acellular (e.g., hyaluronan) elements of the stroma. This study aims to briefly review the primary structural properties of PC stroma and its interaction with cancer cells and summarize the current status of anti-stromal therapies in the management of metastatic PC.
dc.identifier.citationKanat, Ö. ve Ertaş, H. (2018). ''Shattering the castle walls: Anti-stromal therapy for pancreatic cancer''. World Journal of Gastrointestinal Oncology, 10(89), 202-210.
dc.identifier.endpage210
dc.identifier.issn1948-5204
dc.identifier.issue8
dc.identifier.pubmed30147846
dc.identifier.scopus2-s2.0-85052554420
dc.identifier.startpage202
dc.identifier.urihttps://doi.org/10.4251/wjgo.v10.i8.202
dc.identifier.urihttps://www.wjgnet.com/1948-5204/full/v10/i8/202.htm
dc.identifier.urihttp://hdl.handle.net/11452/30062
dc.identifier.volume10
dc.identifier.wos000442012800001
dc.indexed.scopusScopus
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherBaishideng Publishing Group
dc.relation.journalWorld Journal of Gastrointestinal Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectOncology
dc.subjectGastroenterology & hepatology
dc.subjectPancreatic cancer
dc.subjectStroma
dc.subjectStellate cells
dc.subjectHyaluronan
dc.subjectSecreted protein acidic and rich in cysteine
dc.subjectStellate cells
dc.subjectDuctal adenocarcinoma
dc.subjectTumor progression
dc.subjectSparc expression
dc.subjectTargeted therapies
dc.subjectPatient survival
dc.subjectGene-expression
dc.subjectCarcinoma cells
dc.subjectNab-paclitaxel
dc.subjectRetinoic acid
dc.subject.emtreeAngiotensin 2 receptor antagonist
dc.subject.emtreeAntifibrotic agent
dc.subject.emtreeHyaluronic acid
dc.subject.emtreeMicroRNA
dc.subject.emtreeOsteonectin
dc.subject.emtreeRetinol derivative
dc.subject.emtreeVitamin D derivative
dc.subject.emtreeCancer growth
dc.subject.emtreeCancer therapy
dc.subject.emtreeCell interaction
dc.subject.emtreeHedgehog signaling
dc.subject.emtreeHuman
dc.subject.emtreeNonhuman
dc.subject.emtreePancreas cancer
dc.subject.emtreePancreatic stellate cell
dc.subject.emtreePriority journal
dc.subject.emtreeShort survey
dc.subject.emtreeStroma
dc.subject.emtreeUpregulation
dc.subject.scopusCancer; Chronic Pancreatitis; Acinar Cells
dc.subject.wosOncology
dc.subject.wosGastroenterology & hepatology
dc.titleShattering the castle walls: Anti-stromal therapy for pancreatic cancer
dc.typeArticle
dc.wos.quartileQ3
dc.wos.quartileQ3
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Onkoloji Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Kanat_Ertaş_2018.pdf
Size:
1.3 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: